WallachBeth Capital Completes $1.2 Million Private Placement for bioAffinity Technologies

WallachBeth Capital Announces Successful Closing of $1.2 Million Private Placement

WallachBeth Capital LLC, a prominent player in the capital markets, has recently completed a significant private placement for bioAffinity Technologies. This strategic transaction, valued at approximately $1.2 million, marks a crucial moment in both firms' trajectories, enabling enhanced opportunities for investment and growth.

The private placement involved the sale and purchase of 990 shares of the Company’s Series B Convertible Preferred Stock, alongside warrants granting the right to purchase around 6.7 million shares of common stock. This move is not only reflective of confidence in bioAffinity's potential but also emphasizes WallachBeth's dedication to facilitating substantial financial endeavors in the healthcare sector.

As part of the development, the firm disclosed that an existing accredited investor exercised outstanding warrants to purchase 450,000 shares of common stock from previous offerings made in August and October 2024. Notably, the exercise prices for these warrants were reduced from $1.50 to $0.23, thus encouraging immediate engagement from investors. This decision also allowed the issuance of new warrants enabling the acquisition of an additional 1.4 million shares, reflecting a robust demand for bioAffinity's equity.

WallachBeth Capital served as the sole placement agent for this private placement, showcasing its expertise in navigating complex financial transactions. The private offering falls under the exemption from registration requirements as outlined in Section 4(a)(2) of the Securities Act of 1933, affirming its compliance with regulatory frameworks while providing crucial capital to bioAffinity Technologies.

This financial maneuver not only strengthens bioAffinity's capital base but also enhances its positioning in the market, paving the way for future developments. The company plans to channel these funds into driving innovation and expanding operations, underscoring its commitment to advancing health technology solutions.

In addition, WallachBeth’s involvement as a financial advisor during the warrant inducement further illustrates their strategic collaboration with bioAffinity Technologies. With the closing of these transactions, both entities are poised to leverage new opportunities for growth, ultimately aiming to meet the increasing demands of the healthcare sector.

This private placement forms part of a broader strategy for WallachBeth Capital to connect corporate clients with leading institutional investors, thereby supporting issuers and facilitating capital-raising efforts in a competitive landscape. Their diversified service offerings include initial public offerings, PIPE offerings, follow-on issues, and innovative financing solutions.

As both companies look ahead, the successful closure of this private placement sets a precedent for future collaborations and financial transactions within the industry. The anticipated impacts of this capital influx are yet to unfold, but the foundation for growth and advancement has been firmly established through this strategic partnership.

In conclusion, WallachBeth Capital's successful closure of the private placement transaction for bioAffinity Technologies is a significant milestone that underscores the value of strategic financial partnerships in fostering innovation and supporting growth in the healthcare market. With the landscape continuously evolving, both companies are well-positioned to navigate challenges and seize opportunities in the coming years.